authors of the current report, are in favor of a more conservative resection for WD liposarcoma. In this perspective, correct preoperative diagnosis is essential for making the proper decision because the two entities cannot be distinguished intraoperatively.
The role of neoadjuvant treatment still is debated because, to date, no randomized trials of preoperative treatment for retroperitoneal sarcoma have been concluded and reported. The National Comprehensive Cancer Network (NCCN) guidelines offer the option of preoperative radiation therapy, chemotherapy, or both based on lowerlevel evidence without a uniform consensus. The European Society for Medical Oncology (ESMO) guidelines, on the other hand, consider adjuvant/neoadjuvant chemotherapy as an individualized (or investigational) indication and preoperative radiation therapy as only investigational for retroperitoneal sarcomas.
One randomized trial currently is recruiting patients in Europe and North America. It explores the impact of preoperative radiation therapy in primary retroperitoneal sarcoma and includes both WD and DD liposarcomas (EORTC-62092-22092, STRASS, NCT01344018).
Outside of the investigational setting, therefore, the use of neoadjuvant therapies must be decided by a multidisciplinary sarcoma board in the context of high-risk disease or a locally advanced (and/or nearly unresectable) presentation. The main prognostic factors to be considered in decision making for local recurrence and distant metastasis of retroperitoneal sarcomas are histology subtype and tumor grade.
Dedifferentiated liposarcomas are known to exist in at least two variants: intermediate and high grade. The former has a predominant risk of local recurrence, whereas the latter carries a risk reaching 40 % for distant metastasis. For this reason, patients affected by high-grade DD retroperitoneal liposarcoma may be considered for neoadjuvant chemotherapy. 2 The accuracy of preoperative biopsy for evaluating tumor grade may thus become as crucial to the indication for neoadjuvant treatments of high-risk tumors as the accuracy of discriminating between WD and DD liposarcomas.
Data on tumor grade at biopsy were unfortunately not available in the study by Ikoma et al. The relevant finding, nonetheless, is that the accuracy of biopsy for DD liposarcomas is low, and multidisciplinary sarcoma boards should be aware of this.
Computed tomography (CT) scan imaging allows clinicians to anticipate both the diagnosis of retroperitoneal liposarcoma and the possible presence of a dedifferentiated component given that heterogeneous, nonlipomatous highdensity/contrast-enhanced nodules within the main tumoral mass are the usual radiologic presentation of DD liposarcoma. 3 Nevertheless, no radiologic feature has a higher predictive value for DD liposarcoma than histologic diagnosis, making preoperative percutaneous biopsy the gold standard for obtaining a correct preoperative diagnosis without major risk of complications for the patient, tumor seeding, or both. 4 To maximize the accuracy of biopsy for retroperitoneal liposarcoma, two important issues must be addressed. First, biopsy material needs to be of suitable quality and quantity. Core needle biopsy (CNB) should be recommended in all cases because the accuracy of fine-needle aspiration (FNA) may not be sufficient. A needle diameter of 16 G or larger usually is adequate for the histologic diagnosis of soft tissue sarcoma. It also is recommended that multiple cores (4-6) be obtained during the biopsy procedure to collect sufficient tissue for morphologic, immunocytochemical, and molecular diagnostic testing. Ideally, samples also should be collected for fresh-frozen tissue banking, especially if neoadjuvant treatment has been envisaged.
Second, percutaneous biopsy must be planned to provide an adequate sample of the nodular hyperdense component of the mass, which raises more suspicion of dedifferentiation. For this reason, it is best to perform an image-guided biopsy. A positron emission tomography (PET) scan may help to identify hot areas and reduce the risk of underestimating the biologic risk. A previous study from the same institution clearly pointed to the efficacy of image-guided, ''targeted'' biopsy. 5 Hence, the accuracy of a preoperative DD liposarcoma diagnosis may be optimized if percutaneous biopsy is expressly programmed as a ''targeted'' procedure directed to the worst-looking component of the tumor mass on the imaging findings.
This accuracy in the current study by Ikoma et al. was low, but the retrospective nature of the study and the high percentage of biopsies taken before referral (35 %) are clear limitations. Because correct diagnosis is becoming more and more critical to tailoring of the appropriate treatment to the individual patient with retroperitoneal liposarcoma, accurate preoperative biopsy should be planned to identify the areas at higher biologic risk. Contrast-enhanced CT scan and PET scan, when clinically sound, should be used to guide percutaneous biopsy.
Every effort should be made to refer retroperitoneal sarcoma patients to specialized centers from the very initial observation to maximize the accuracy of their workup. This is critical to optimizing the treatment strategy and maximizing the chance of cure.
